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Abstract
Background:  Previous studies have suggested that exercise in patients with intermittent
claudication (IC) may induce a systemic thrombo-inflammatory response. The effect of secondary
prevention therapy on this response is unknown. This study aimed to investigate the effects of
treadmill exercise on markers of coagulation activation, inflammation and renal function in patients
with IC, receiving aspirin and statin therapy compared to healthy controls.
Methods: Samples were taken before, immediately and 1 hour after exercising on a treadmill in
20 patients with IC and 20 healthy volunteers. Interleukin-6 (IL-6), thrombin-anti-thrombin
complex (TAT) and fibrin D-dimer were measured by ELISA. High sensitivity CRP (HsCRP) and
urinary albumin were measured via a nephelometric technique, urinary protein via a turbidometric
assay and N-acetyl-β-D-glucosaminidase (NAG) via a colorimetric assay.
Results: Elevated baseline levels of Hs-CRP, IL-6, white cell counts, D-dimer and urinary NAG
occurred in patients with IC compared to volunteers (p > 0.05). Following exercise there was no
increase in Hs CRP or IL-6. D-dimer levels significantly increased following exercise in the patients
and volunteers. TAT levels increased immediately after exercise in the patient group only and were
significantly increased at 1 hour in both patients and volunteers. A transient rise in the protein
creatinine ratio occurred in both groups (p < 0.007), and in albumin creatinine ratio in the patient
group. There was no change in urinary NAG.
Conclusion: Elevated markers of inflammation occurred in patients with IC on statin and aspirin
therapy but these did not increase following exercise. However, acute exercise resulted in a
prothrombotic state evident in both groups, although this was more prolonged in patient with IC.
The clinical significance of these findings in patients who are known to be at an increased risk of
cardiac and other thrombotic event are unclear.
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Background
Regular, supervised, aerobic exercise has been shown to
improve maximum walking distance and quality of life in
patients with peripheral arterial disease and intermittent
claudication (IC) [1]. However, current evidence suggests
that exercise in patients with intermittent claudication
may induce a systemic thrombo-inflammatory response
[2,3]. Repeated bouts of muscle ischaemia induced by
exercising to the onset of muscle pain, followed by reper-
fusion on rest, results in the generation of oxygen-derived
free radicals (ODFR), subsequent neutrophil activation,
release of arachadonic acid from membrane phospholip-
ids, pro-inflammatory eicosanoids and cytokines [3-6].
ODFR, in particular the hydroxyl radical, cause lipid per-
oxidation, resulting in structural damage and activation of
the vascular endothelium, increased vascular permeability
and systemic capillary endothelial swelling [2,3,5]. A con-
sequence of this altered capillary permeability is an
increase in transcapillary leak of plasma proteins, result-
ing in increased renal albumin excretion [7]. Increases in
urinary albumin excretion (expressed as the albumin cre-
atinine ratio [ACR]) and protein creatinine excretion
(PCR) have been demonstrated post- treadmill exercise in
patients with intermittent claudication [7-10]. The
increases in ACR have been shown to be attenuated by
exercise therapy [9]. It is not clear if secondary prevention
therapy, which includes aspirin and statin is able to atten-
uate the increase in glomerular permeability. The effect of
exercise on tubular function is also unclear. N-acetyl-β-D-
glucosaminidase (NAG) is a renal lysosomal enzyme
found primarily in the proximal convoluted tubule. NAG
is involved in the breakdown of glycoproteins [11].
Increased lysosomal turnover, such as that caused by pro-
teinuria results in a small increase in urinary NAG. Larger
increases represent renal, particularly tubular insult [12].
To the best of our knowledge, urinary NAG has not been
assessed as a marker of renal dysfunction secondary to a
possible exercise- induced inflammatory response.
In addition to exercise induced endothelial and leucocyte
activation, there have been concerns that exercise may
result in a pro-thrombotic state. Raised levels of various
markers of coagulation such as D-dimer and thrombin-
anti-thrombin complex (TAT) have been shown to occur
in patients with intermittent claudication [13]. D-dimer is
a breakdown product formed when plasmin acts on cross-
linked fibrin. It may therefore be considered a marker of
increased deposition of intra-vascular cross-linked fibrin
(up regulation of coagulation cascade) or reflect up-regu-
lation of the fibrinolytic pathway [14]. Raised levels of
TAT complex in plasma are indicative of in-vivo thrombin
generation [15]. To date, two studies have found an
increase in thrombin generation following exercise, and
only one of these showed an increase in fibrin breakdown
in patients with IC who were not on statin therapy. Thus
there is a possibility that exercise may lead to a pro-throm-
botic state [16,17]. Statin therapy has been shown to
reduce thrombin generation, and it is unclear what effect
it may have on response to exercise in these patients [18].
In this study, we wished to determine if these observed
changes in coagulation and inflammation would occur in
patients maintained on statin therapy.
The aims of this observational study were to examine the
effects of treadmill exercise on markers of inflammation,
coagulation activation and renal function in patients with
intermittent claudication on aspirin and statin therapy
compared to healthy, age matched volunteers. The follow-
ing parameters were measured: plasma interleukin-6 (IL-
6), high sensitivity CRP (hsCRP), white blood cell count,
thrombin-anti-thrombin complex (TAT) and fibrin D-
Dimer (fDD), urinary protein creatinine ratio (PCR), ACR
and NAG.
Patients and methods
The study population consisted of 20 patients with inter-
mittent claudication and 20 healthy volunteers (table 1).
The local research ethics committee approved the study
and written consent was obtained. Patients were required
to have a diagnosis of chronic, stable intermittent claudi-
cation for at least six months and an ankle brachial pres-
sure index (ABPI) of = 0.8. All patients were on secondary
prevention therapy which included 75 mg of aspirin and
statin therapy of at least six weeks duration. Statin therapy
consisted of 40 mg of simvastatin or pravastatin or 10 mg
Table 1: Patient and volunteer demographics
Volunteers (n = 20) Claudicants (n = 20)
Male:Female 11:9 16:4
Mean Age (SD) 63 (10) 68 (8)
Mean ABPI (SD) 1.14 (0.10) 0.62 (0.13)
Smokers
Never 13 1
Reformed 5 12
Current 2 7
Aspirin Therapy 0 20Thrombosis Journal 2006, 4:9 http://www.thrombosisjournal.com/content/4/1/9
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of atorvastin, depending on an individual General practi-
tioners prescribing practice. Patients were commenced on
statin therapy irrespective of their initial baseline choles-
terol level. Patients on clopidogrel, anti-inflamatory ther-
apy, cilostazol or praxilene were excluded as were patients
with diabetes. Patients who were judged unable to exer-
cise due to other co-existing morbidities were excluded.
The healthy age-matched volunteers were recruited from
the surgical out-patient clinics. The presence of cardiovas-
cular disease was excluded by medical questionnaire and
physical examination including ABPIs. All volunteers had
an ABPI greater than or equal to 1. No control subject was
taking anti-platelet, anti-inflammatory, statin or steroidal
therapy for at least 14 days prior to testing. The demo-
graphic details for the patient and volunteer group are
shown in table 1.
Treadmill exercise
Patients with claudication walked on a treadmill (speed
3.5 km/h, incline 5 degrees) to their maximum walking
distance. Exercise duration, time to onset and resolution
of typical calf pain was recorded for all patients. Healthy
controls walked for 3 minutes and 20 seconds which cor-
responded to the average patient exercise duration and
represented a walking distance of 194 metres.
Blood Sampling and processing
Patients and volunteers attended for exercise after 9 am in
the morning and were fasted for at least 6 hours having
abstained from unaccustomed physical activity for the
preceding 24 hours. All subjects rested for 30 minutes in a
supine position prior to initial blood sampling. An 18G
cannula was inserted into a large vein in the ante-cubital
fossa. Patency was maintained by flushing the cannula
with 5 ml boluses of 0.9% normal saline between sam-
pling. Blood samples were collected using a "double
syringe" technique and without the use of a tourniquet.
The first 10 millilitres of blood collected was discarded.
Blood was centrifuged (4 degrees centigrade at 2500 G)
and the plasma separated, snap-frozen in liquid nitrogen
and stored at -80 degrees centigrade for subsequent anal-
ysis. Further blood samples were collected immediately
after the cessation of exercise and following a period of
one hour of rest.
Urine collection
On arrival, subjects emptied their bladder completely.
After resting in a supine position for 30 minutes a mid-
stream sample or urine was provided. Further samples
were obtained in a similar manner 10 minutes after exer-
cise and after 1 hour of recovery with complete voiding
between each sample. Samples were frozen and stored at
-20°C until analysis.
Analysis of samples
The following thrombo-inflammatory markers were
measured at all timepoints: Plasma IL-6, HsCRP, TAT
complex, Fibrin D-dimer, urinary protein, albumin and
NAG. White cell count was assessed at baseline and imme-
diately post-exercise.
IL-6 assay
Plasma IL-6 was measured using a high sensitivity ELISA
(Diaclone, Cedex, France). All samples were assayed in
duplicate and all subjects' samples were analysed on the
same run. The limit of detection was 1 pg/ml. The intra-
assay coefficient of variation (CV) was 4.6%. The inter-
assay CV was 6.7%.
High-sensitivity CRP
HsCRP was measured using a commercially available rate
nephelometric technique on a BN ProSpec analyser (Dade
Behring Ltd, Milton Keynes, UK). The limit of detection
was 0.175 mg/L CRP. Intra-assay CV was 3.5%. Inter-assay
CV was 3.4%.
White cell count (WBC)
White cell count was performed as part of an automated-
full blood count in the Haematology Laboratory, ARI,
using the Bayer Advia 120 System (Bayer, Newbury, UK.)
TAT complex
TAT was measured by ELISA (Enzygnost, Dade-Behring,
Sysmex, Milton Keynes, UK). All samples were assayed in
duplicate and all patient samples were analysed on the
same run. Intra-assay CV was 3.6%. The inter-assay CV
was 4.3%.
Fibrin D-dimer
D-dimer was measured by immunoassay on the mini-
Vidas instrument (Biomerieux UK Ltd, Basingstoke, UK).
All samples were assayed in duplicate and all patient sam-
ples were analysed on the same run. Inter-assay CV was
4.7%.
Urinary NAG
NAG was measured using a commercial colorimetric assay
(PPR Diagnostics Ltd, London, UK) on a Roche Modular
P system (Roche Diagnostics Ltd, East Sussex, UK). The
limit of detection was 0.25 μmol/min/l NAG. Intra-assay
CV was 3.9%. The inter-assay CV was 3.8%. NAG was
expressed as a ratio with urinary creatinine so as to adjust
for differences in urinary flow of the sample (i.e. μmol/h/
mmol creatinine). The reference range is quoted as 0.12–
0.47 μmol/min/mmol creatinine.
Urinary protein
Urinary protein was measured using a turbidimetric tech-
nique on the Roche Modular P system (Roche DiagnosticsThrombosis Journal 2006, 4:9 http://www.thrombosisjournal.com/content/4/1/9
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Ltd, East Sussex, UK). The analyser was calibrated using
commercially available human albumin/globulin stand-
ards of known concentration (Preciset U/CSF Protein,
Roche Diagnostics GmbH, Germany). The limit of detec-
tion was 20 mg/l for urinary protein. The manufacturers
quoted intra-assay C.V. was 1.0–5.2% and the inter-assay
C.V. was 0.6–1.0%.
Urinary albumin
Urinary albumin was measured using a nephelometric
monoclonal antibody method on a BN Prospec analyser
(Dade Behring Ltd, Milton Keynes, UK). The analyser was
calibrated using N-Protein Standard and quality control
samples were included in each run (Precinorm Albumin
and Precipath Albumin, Roche Diagnostics Limited, Sus-
sex, UK). The limit of detection was 1 mg/l for urinary
albumin. The manufacturers quoted intra-assay C.V. was
1.2–1.6% and the inter-assay C.V. was 2.8–3.3%.
Urinary creatinine
Creatinine was measured using an optimised kinetic Jaffe
reaction (32) on the Roche Modular P system (Roche
Diagnostics Limited, Sussex, UK). The analyser was cali-
brated using C.f.a.s (Calibrator for automated systems)
and standard controls were included in each run (Preci-
norm Albumin and Precipath Albumin, (Roche Diagnos-
tics Limited, Sussex, UK). The limit of detection was 2
mmol/l and the manufacturers quoted intra-assay C.V.
was 1.1–2.1%, inter-assay C.V. was 1.2–2.2 %. Both uri-
nary protein and albumin concentrations were correlated
for urine flow by factoring by creatinine concentration of
the sample (i.e. mg/mmol creatinine). The technique of
using single voided urine samples to estimate quantitative
proteinuria is well validated and accurate [19].
Statistical methods
All statistical analysis was performed using SPSS Version
11.5 for windows. All data were non-parametrically dis-
tributed. Initial analysis was via Friedmans test. Between
time-point comparisons were performed using the Wil-
coxon signed-rank test. Thus for each patient the post-
exercise values were compared to their original baseline
values and therefore each patient served as their own con-
trol. We acknowledge that there are a large number of pos-
sible confounding variables which could influence an
individual patients response to exercise. However, it was
felt that subgroup analysis of a patient cohort of 20 would
be inappropriate. The difference in baseline measure-
ments between groups was tested using the Mann-Whit-
ney U-test. Chi-squared test was used to measure variation
in demographic parameters between the groups. Expert
statistical advice was sought from the Department of Sta-
tistics, University of Aberdeen.
Results
The mean maximal walking time of the patients was 3
minutes 20 seconds (SD 130 seconds) which corre-
sponded to a mean distance of 320 m. None of the
healthy volunteers complained of lower limb pain during
the exercise
IL-6
In the healthy volunteers 78% of samples returned IL-6
values below the detectable range of the assay (<1.1 pg/
ml). In patients with IC 42% of IL-6 levels were below the
detectable range. For statistical analysis all values below
the detectable range were given the value 0 pg/ml IL-6.
Baseline IL-6 values were higher in patients with IC (p =
0.001). There was no change in plasma IL-6 concentration
following exercise (table 2).
HsCRP
Baseline hsCRP values were higher in patients with IC
compared to volunteers (p = 0.035). CRP levels were unaf-
fected by exercise in the patients with IC or healthy volun-
teers (table 2).
White Cell Count (WBC)
Baseline WBC was significantly higher in patients with IC
compared to volunteers (p = 0.011). WBC increased sig-
nificantly following exercise in both groups (p < 0.05).
The median (range) increased from 7.6 (5.6–13.4) to 8.9
(7.1–17) immediately following exercise in patients with
IC. Corresponding values for the volunteers prior to and
immediately following exercise were 6.5 (4.4–11.0) and
7.8 (5.2–14) respectively.
Table 2: Plasma markers of inflammation following exercise.
Assay Group Baseline Immediately post-
exercise
1 hour post-
exercise
P value
IL-6 HV 0.0 (0.0–4.9) 0.0 (0.0–6.2) 0.0 (0.0–4.7) >0.05
IC 1.6 (0.0–15.7) 1.6 (0.0–12.3) 1.7 (0.0–15.3) >0.05
HsCRP HV 0.9 (0.2–16.2) 1.0 (0.2–13.5) 0.9 (0.2–12.6) >0.05
IC 2.9 (0.5–23.0) 3.0 (0.5–24.7) 2.9 (0.5–20.1) >0.05
HV = healthy volunteers, IC = patients with intermittent claudication. Numbers represent medians with the range in brackets. P values represent 
Friedman testThrombosis Journal 2006, 4:9 http://www.thrombosisjournal.com/content/4/1/9
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D-dimer
Fibrin D-dimer levels were significantly higher in patients
with IC compared to healthy volunteers (median 520 ng/
ml vs 381 ng/ml [p = 0.003]). Following exercise, D-dimer
levels increased in both groups (Figure 1). Median per-
centage increase in volunteers was 7% (range -18% to
71% [p = 0.035]) and in patients with IC was 9% (range -
7% to 88% [p = 0.008]). The magnitude of the changes in
both groups was comparable. D-dimer levels remained
elevated at 1 hour in the patients with IC.
TAT-complex
Baseline TAT levels did not differ between patients with IC
and volunteers. TAT rose immediately post exercise in
patients with IC and remained elevated at 1 hour (Figure
2). The median % change was 128% (range -43% to 400%
[p = 0.003]). There were no immediate changes in TAT fol-
lowing treadmill exercise in volunteers, however, TAT lev-
els were significantly elevated at 1 hour compared to
baseline (p = 0.009) (Figure 2).
Urinary PCR/ACR
Baseline PCR and ACR did not differ between the groups
although there was a trend for higher urinary protein lev-
els in patients with IC. After exercise PCR increased in
both volunteers (p = 0.003) and patients with IC (p =
0.005). There was a significant increase in ACR following
exercise in patients with IC only (p= 0.025) which
returned to baseline values at 1 hour (table 3).
Urinary NAG
Patients with IC had higher baseline NAG levels com-
pared to healthy volunteers (P = 0.011). There was no
change in urinary NAG levels post-exercise (table 3).
Discussion
In this study, elevated baseline levels of the inflammatory
markers Hs-CRP, IL-6, and white cell counts were
observed in patients with intermittent claudication
despite statin and aspirin therapy. This chronic inflamma-
tory state has previously been documented in patients
with intermittent claudication who were not receiving
both statin and aspirin therapy [20,23]. Recently concern
has risen, that exercise in patients with intermittent clau-
dication may result in yet a further increase in the level of
these inflammatory markers [3].
Plasma TAT complex following treadmill exercise Figure 2
Plasma TAT complex following treadmill exercise. Healthy 
volunteers are represented by the grey boxes, and patients 
with intermittent claudication by the black boxes. A = base-
line; B = immediately post-exercise; C = 1 hour post-exer-
cise. Data presented as box-plots- line in centre of box 
represents the median value; the box represents the inter-
quartile range and the whiskers represent the range. Markers 
out with the whiskers are outliers i.e. cases with values 
between 1.5 and 3 box lengths from the upper or lower edge 
of the box. P- values are Wilcoxon signed-rank test com-
pared to baseline. Friedman test: P < 0.05
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Plasma D-Dimer following treadmill exercise Figure 1
Plasma D-Dimer following treadmill exercise. A = baseline; B 
= immediately post-exercise; C = 1 hour post-exercise. Data 
presented as box-plots- line in centre of box represents the 
median value; the box represents the inter-quartile range and 
the whiskers represent the range. Markers out with the 
whiskers are outliers i.e. cases with values between 1.5 and 3 
box lengths from the upper or lower edge of the box. P- val-
ues are Wilcoxon signed-rank test compared to baseline. 
Friedman test: P < 0.05
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In this study, the inclusion of age matched healthy con-
trols allowed us to determine if any observed effects were
due to exercise alone or due to a pro-inflammatory
response induced by muscle ischaemia in patients with
IC. Thus the duration of treadmill exercise in the volun-
teer group was limited to allow direct comparison with
the patients with IC. The groups were not matched in rela-
tion to smoking and each patient and volunteer were used
as there own control. We found no increase in Hs CRP or
IL-6 following exercise in patients with IC on aspirin and
statin therapy or in the healthy volunteers [24]. The effect
of acute exercise on high sensitivity CRP has not been
reported before, but exercise training has been shown to
reduce levels of CRP [2,25]. Only one previous study has
examined the effect of exercise on IL-6 levels, a precursor
of CRP, and shown this to be increased pre and post-exer-
cise in 20 patients with IC compared to 20 healthy con-
trols [6]. These patients were not on statin therapy which
has been shown to reduce IL-6 and CRP production in the
endothelial and liver cells [26,27].
Despite the lack of inflammatory response, exercise did
appear to result in an imbalance between the thrombotic
and fibrinolytic pathways in both patients with IC and
healthy controls. We have previously shown TAT levels to
be increased in patients with critical limb ischaemia, but
not in patients with IC compared to controls [13]. Simi-
larly, in this study, baseline TAT levels did not differ
between patients with IC and healthy volunteers despite
the fact that there was a much higher preponderance of
smokers in the patient group. D-dimer baseline levels
were elevated as would be expected in the patient group
[13,28,29]. Following treadmill exercise TAT levels
increased in the patients with IC and in volunteers. How-
ever, the increase in TAT levels was immediate and more
prolonged in the patients with IC. In healthy volunteers
changes in TAT levels have been shown to vary depending
on the nature of exercise and fitness of the individual, but
it is surprising to observe a significant rise in TAT at 1 hour
following limited exercise [30,31]. A rise in D-dimer levels
was also observed in both groups suggesting concomitant
up-regulation of the fibrinolytic pathway, but this was
only evident immediately after exercise. Thus the pro-
thrombotic effect of exercise, as assessed by TAT levels was
more prolonged. Mustonen et al [17], showed exercise
induced increases in both TAT and D-dimer, whereas a
smaller study by Burns et al showed an increase in TAT but
not D-dimer post-exercise in patients with IC [16]. The
findings of the later study, like ours suggest an imbalance
in the fibrinolytic system and a pro-thombotic state. This
finding which is more pronounced in the patient group
has occurred despite the use of statins which have been
shown to reduce thrombin generation [18]. While it
would have been desirable to have assessed the effect of
exercise on these pro-thrombotic markers in patients with
IC who are not on aspirin and statin therapy this would be
difficult to achieve and indeed unethical. It would also
not be relevant to current accepted practice of the manage-
ment of patients with IC. The effect, of exercise training on
TAT levels are unknown, but a recent study has shown that
exercise therapy results in a reduction in the levels of PAI-
1 an inhibitor of fibrinolysis in patients with intermittent
claudication [33]. However, the recent suggestion that
successful lower limb angioplasty may reverse any
thrombo-inflammatory effects of exercise seen in patients
with IC may be inappropriate given the changes observed
in the volunteer group [10].
Importantly, this study is the first to assess the effect of
exercise on urinary NAG which is a sensitive index of sub-
clinical proximal tubular damage [34]. NAG was elevated
in patients with intermittent claudication compared to
volunteers at baseline suggesting on-going renal insult in
patients with intermittent claudication. Increases in uri-
nary NAG excretion have been demonstrated in patients
undergoing aortic surgery [35] and in patients with critical
limb ischaemia [36] but has not previously been docu-
mented in patients with IC. Reassuringly, exercise in
patients with IC did not result in a rise in urinary NAG.
The baseline PCR and the ACR, which are markers of
glomerular permeability, were similar in patients with IC
and volunteers. The PCR increased in both groups imme-
diately post-exercise but returned to baseline levels at 1
hour. The ACR, increased only in the patient with IC
Table 3: Renal function following exercise.
Assay Group Baseline Immediately post-
exercise
1 hour post-
exercise
P value
PCR HV 7.0 (4.0–25.0) 9.0† (5.0–34.0) 9 (5.0–31.0) 0.014
IC 7.0 (2.0–52.0) 10.5† (2.0–63.0) 7.5 (3.0–58.0) 0.005
ACR HV 0.9 (0.9–13.2) 1.0 (0.9–19.6) 0.9 (0.9–20.2) >0.05
IC 1.0 (0.9–34.2) 1.75‡ (0.9–34.7) 1.0 (0.9–31.3) 0.046
NAG HV 0.7 (0.4–1.5) 0.8 (0.3–2.1) 0.8 (0.4–1.4) >0.05
IC 1.4 (0.2–7.8) 1.4 (0.2–6.8) 1.2 (0.2–5.0) >0.05
HV = healthy volunteers, IC = patients with intermittent claudication. Numbers represent medians with the range in brackets. P values represent 
Friedman's test. ‡p < 0.05, †p < 0.001 (Wilcoxon signed rank test, comparisons made with baseline values).Thrombosis Journal 2006, 4:9 http://www.thrombosisjournal.com/content/4/1/9
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immediately following treadmill exercise and returned to
baseline levels at 1 hour. The clinical significance of this
increase in ACR is unclear but it has been shown to be
attenuated following exercise training [9]. While the rise
in PCR and ACR post exercise in patients with IC has pre-
viously been documented [7-10,36] this study has dem-
onstrated how transient this phenomenon is in patients
with IC and emphasises that an increase in glomerular
permeability also occurs in healthy volunteers.
We conclude that in patients with intermittent claudica-
tion on secondary prevention therapy including aspirin
and a statin, there is evidence of an on going chronic
inflammatory response. However, in these patients exer-
cising to maximum walking distance did not result in a
rise in the inflammatory markers HsCRP or IL-6. Exercise
resulted in a transitory increase in glomerular permeabil-
ity but no change in renal tubular function. Exercise did
result in increased TAT levels suggesting in-vivo thrombin
generation in both patients with IC and healthy volun-
teers, but the effect in patients was immediate and more
prolonged. The increase in D-dimer levels was more tran-
sitory suggesting that an imbalance in the thrombotic and
fibrinolytic pathway may exist despite statin and
antiplatelet therapy. Currently, the clinical significance of
this mismatch in the thrombotic and fibrinolytic system is
unclear and further studies are required. However, its
occurrence in patients with IC who have an increased risk
of adverse thrombotic events may be a cause for concern.
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